Levetiracetam Differentially Alters CD95 Expression of Neuronal Cells and the Mitochondrial Membrane Potential of Immune and Neuronal Cells in vitro by Susannah K. Rogers et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 18 February 2014
doi: 10.3389/fneur.2014.00017
Levetiracetam differentially alters CD95 expression of
neuronal cells and the mitochondrial membrane potential
of immune and neuronal cells in vitro
Susannah K. Rogers1†, Lee A. Shapiro2,3,4†, Richard P.Tobin2, BenjaminTow 2, Aleksej Zuzek 2,
Sanjib Mukherjee2,3,4 and M. Karen Newell-Rogers2,4*
1 Department of Anthropology, University of Texas, Austin, TX, USA
2 Department of Surgery, Texas A&M University Health Science Center, Temple, TX, USA
3 Central Texas Veterans Health Care System, Temple, TX, USA
4 Scott andWhite Hospital, Temple, TX, USA
Edited by:
Batool F. Kirmani, Texas A&M Health
Science Center College of Medicine,
USA
Reviewed by:
Ashok K. Shetty, Texas A&M Health
Science Center College of Medicine
at Scott &White, USA
Batool F. Kirmani, Texas A&M Health
Science Center College of Medicine,
USA
*Correspondence:
M. Karen Newell-Rogers, Department
of Surgery, Texas A&M University
Health Science Center, Medical
Research Building RM 114B, 2401
South 31st Street, Temple, TX 76504,
USA
e-mail: mknewell@gmail.com
†Susannah K. Rogers and Lee A.
Shapiro have contributed equally to
this work.
Epilepsy is a neurological seizure disorder that affects over 100 million people world-
wide. Levetiracetam, either alone, as monotherapy, or as adjunctive treatment, is widely
used to control certain types of seizures. Despite its increasing popularity as a relatively
safe and effective anti-convulsive treatment option, its mechanism(s) of action are poorly
understood. Studies have suggested neuronal, glial, and immune mechanisms of action.
Understanding the precise mechanisms of action of levetiracetam would be extremely ben-
eficial in helping to understand the processes involved in seizure generation and epilepsy.
Moreover, a full understanding of these mechanisms would help to create more efficacious
treatments while minimizing side-effects. The current study examined the effects of lev-
etiracetam on the mitochondrial membrane potential of neuronal and non-neuronal cells,
in vitro, in order to determine if levetiracetam influences metabolic processes in these cell
types. In addition, this study sought to address possible immune-mediated mechanisms
by determining if levetiracetam alters the expression of immune receptor–ligand pairs.The
results show that levetiracetam induces expression of CD95 and CD178 on NGF-treated
C17.2 neuronal cells. The results also show that levetiracetam increases mitochondrial
membrane potential on C17.2 neuronal cells in the presence of nerve growth factor. In
contrast, levetiracetam decreases the mitochondrial membrane potential of splenocytes
and this effect was dependent on intact invariant chain, thus implicating immune cell inter-
actions.These results suggest that both neuronal and non-neuronal anti-epileptic activities
of levetiracetam involve control over energy metabolism, more specifically, m∆Ψ. Future
studies are needed to further investigate this potential mechanism of action.
Keywords: epilepsy, Keppra, splenocytes, C17.2, in vitro, Fas, FasL
INTRODUCTION
Epilepsy is a neurological disorder that affects approximately 65
million people worldwide. While numerous treatment options
are available to control seizures associated with epilepsy, approx-
imately 20–30% of epileptic patients are resistant to treatment.
Pharmaceutical and biomedical device companies continue to
develop new treatments that are more efficacious, while minimiz-
ing undesirable side-effects. One such drug, levetiracetam, alone
as a monotherapy, or combined with another treatment as an
adjunct, is widely used to control partial onset and generalized
seizures (1). Despite its use as a relatively safe and effective anti-
convulsant treatment option, the precise mechanism(s) of action
are not fully understood.
The anti-epileptic effects of levetiracetam may occur, at least
in part, by acting directly on neurons. For example, levetiracetam
is known to bind to the synaptic vesicle protein SV2A (2) and to
inhibit presynaptic calcium channels (3). Studies have shown that
levetiracetam may also exert its anti-epileptic effects by reducing
calcium currents in CA3 pyramidal neurons of the hippocam-
pus (4), or by rescuing neurons in the hippocampus and dentate
gyrus from death (5). Another possibility is that levetiracetam
alters mitochondrial membrane potential (m∆Ψ), although the
reports using the in vivo perforant pathway stimulation paradigm
are conflicting. In one study, levetiracetam effectively mitigated
mitochondrial dysfunction in the hippocampus following estab-
lished status epilepticus (6), but not at acute time points after the
onset of status epilepticus (7). Thus, it is unclear if, or to what
extent, the therapeutic effects of levetiracetam can be attributed to
its neuronal interactions.
While the purpose of the current study is to determine if there
are direct effects of levetiracetam on neuronal and immune cells,
other studies have suggested glial cell mechanisms of action. For
example, Ueda et al. (8) suggested that levetiracetam exerts its
neuroprotective effects through its actions on glial cells. Sim-
ilarly, Haghikia et al. (9) showed that levetiracetam has anti-
inflammatory effects on astrocytes. Consistent with this finding,
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Kim et al. (10) showed that levetiracetam reduced gliosis in epilep-
tic brains and inhibited IL-1B, and Stienen et al. (11) showed that
the anti-inflammatory effects of levetiracetam on astrocytes may
be mediated by TGFβ1.
In addition to effects in the CNS, levetiracetam could also be
exerting its effects in the periphery. Supporting this notion are
the results of a previous study demonstrating that levetiracetam
inhibits the function of some CD8+ T Lymphocytes (12). Such
interactions with the peripheral immune system might explain the
increased incidence of pharyngitis and rhinitis in levetiracetam-
treated patients (13–18). However, studies are lacking that provide
a thorough analysis of the effects of levetiracetam on peripheral
immune cells.
Understanding the mechanism(s) of action of levetiracetam is
important because this knowledge could lead to more efficacious
treatments and better understanding of the epileptic condition.
Due to the lack of a unified theory for the mechanism(s) of
action, the current study was designed to determine if levetirac-
etam affects the m∆Ψ of peripheral immune cells and neuronal
cells. Moreover, this study sought to address possible immune-
mediated mechanisms by determining if levetiracetam alters the
expression of immune receptor–ligand pairs.
MATERIALS AND METHODS
CELL LINES
C17.2
The C17.2 cell line is an immortalized mouse neural progeni-
tor cell line capable of differentiation in vitro. The cell line was
established by retroviral-mediated transduction of the avian myc
oncogene into mitotic progenitor cells of neonatal mouse cere-
bellum from a CD1×C57BL/6 mouse. The C17.2 line of neural
stem cells responds to NGF by differentiating into more mature
neuronal phenotypes and has been used extensively to monitor
developmental regulation of mouse neurons (19). We employed
this cell line as a model of mouse neuronal cells.
In vitro stimulations
C17.2 cells were either untreated, or treated with nerve growth fac-
tor (NGF) at 0.4 nM final concentration. All cells were treated with
levetiracetam or vehicle for 48 h, at the following concentrations:
0.5µm, 15µm, 0.15 mM, or 1.5 mM.
Mice
Eight- to ten-week-old C57BL/6J male mice were purchased
from Jackson Labs. Invariant chain (CD74)-deficient mice (IiDef)
(C57BL/6 background) were purchased from Jackson Labs and
bred at the Scott and White Healthcare animal facility to main-
tain homozygosity. Mice were housed in the Scott and White
Healthcare animal facility according to IACUC regulations.
Spleen cell isolation
Mice were sacrificed and spleens were removed. Splenocytes were
dissociated by passing spleens through 40µm cell strainers. Red
blood cells were lysed using GEY’S buffer (20). Cells were then
cultured at 1.0106 cells/mL in 6 well plates. Cells were grown
in RPMI 1640 (Invitrogen) supplemented with 5% fetal bovine
serum (Invitrogen) in a humidified 5% CO2 incubator at 37°C
for the designated time period. Splenocytes were then treated with
levetiracetam or vehicle for 48 h, at the following concentrations:
0.5µm, 15µm, 0.15 mM, or 1.5 mM.
Flow cytometry
For cell surface markers the cells were first blocked with FC
Block (BD Bioscience) and then stained with the following anti-
bodies; MHCII, CD3ε, CD80, CD86, Fas (CD95), and CD178
(BD Bioscience). Cells were analyzed using a BD FACS Canto II
flow cytometer and the data was analyzed using FlowJo software
(TreeStar Inc.).
Mitochondrial membrane potential (M∆Ψ)
To assess the possibility that levetiracetam has direct effects on
mitochondrial function, mitochondrial activity was assessed using
MitoTracker Red CM-H2XRos (Life Technologies), a mitochon-
drial dye that fluoresces as a function of m∆Ψ. Tightly regu-
lated m∆Ψ is essential for maintaining physiological function(s),
including appropriate mitochondrial substrate selection for gener-
ating ATP and for maintaining cell viability. Cells were treated with
MitoTracker Red and allowed to incubate in the dye for 20 min
prior to analysis using a BD FACS Canto II flow cytometer. The
flow cytometer measures mean fluorescent intensity per cell. Cells
were untreated, treated with NGF, treated with levetiracetam or
NGF+ levetiracetam, as described above in the in vitro stimula-
tion. For each treatment group, a minimum of four separate assays
were performed in triplicate.
Lysosomal acidity
To assess the effects of levetiracetam on lysosomal pH, we used the
fluorescent dye Lysosensor Green (Life Technologies). Lysosensor
Green produces increased fluorescence intensity at lower pH. Cells
were analyzed using a BD FACS Canto II flow cytometer.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6
(GraphPad Software Inc.). For comparisons between splenocytes
from C57BL/6J and IiDef , a paired t -test was used with a signif-
icance cut-off of P < 0.05. For all other analysis, repeated mea-
sures ANOVA was used with post hoc planned comparisons using
Dunnett’s correction factor.
RESULTS
Previous studies have indicated mitochondrial differences in the
presence of levetiracetam (6, 7). Therefore, we determined if these
differences were specific for neuronal or immune cells. Analy-
sis of m∆Ψ in C17.2 cells revealed no significant differences in
the absence of NGF (Figure 1A). In the presence of NGF, leve-
tiracetam resulted in a significant increase (Figure 1A) in m∆Ψ
at all concentrations tested (1.5µm. p< 0.03; 15µm, p< 0.05;
0.15 mM, p< 0.04; 1.5 mM, NS). It is pertinent to note that treat-
ment with levetiracetam did not cause any observable alterations
to the morphology of the C17.2 cells, either with or without
NGF (data not shown). In contrast to the increased m∆Ψ in
the presence of NGF and levetiracetam, the impact of levetirac-
etam on spleen cells (Figure 1B) was a significant reduction
in m∆Ψ (p< 0.007). This reduction appeared to be invariant
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FIGURE 1 | Changes in mitochondrial membrane potential following
treatment with levetiracetam. (A) Mean fluorescence intensity (MFI) of
Mitotracker Red as a measure of relative mitochondrial membrane
potential in C17.2 cells at 48 h post treatment with NGF with or without
levetiracetam (Lev). (B) MFI Mitotracker Red in C57BL/6 splenocytes 48 h
after treatment with or without 0.15 mM Lev. (C) MFI Mitotracker Red in in
IiDef splenocytes 48 h after treatment with or without 0.15 mM Lev.
(D)Table depicting percent change from NGF treatment alone, compared
to NGF treatment in the presence of doses of levetiracetam. *Denotes a
p-value<0.05.
chain dependent, as splenocytes from mice deficient in invariant
chain showed no significant changes in m∆Ψ in response to
levetiracetam (Figures 1C,D).
Elevated m∆Ψ can be associated with elevated CD95 (21,
22). Therefore, to address the possibility that levetiracetam alters
receptor–ligand pairs on neurons, we used the mouse neuronal
stem cell line, C17.2, which can be differentiated in the presence
of NGF. We assessed CD95, a member of the BGF superfam-
ily and its ligand, FasL (CD178) to determine if levetiracetam
can influence cell proliferation, differentiation, and survival. We
also examined alterations in the co-stimulatory molecules B7.1
(CD80), or B7.2 (CD86) to assess the potential of levetiracetam to
alter co-stimulation of T cell activation. The results from analy-
sis of C17.2 cells revealed that levetiracetam treatment alone had
no significant effects on CD95 (Figure 2A), CD178 (Figure 2B),
CD80 (Figure 2C), or CD86 (Figure 2D). In the presence of
NGF, no significant differences were observed for CD95, CD178,
CD80, or CD86 at the 1.5 or 15µm concentrations. However, at
0.15 and 1.5 mM, a significant increase in CD95 (p< 0.02 and
p< 0.001, respectively) was observed. At these latter two con-
centrations, no significant differences were observed for CD80
or CD86. For CD178, no significant differences were observed
for the three lowest concentrations of levetiracetam, but at the
1.5 mM concentration, a significant increase was observed for
CD178 (p< 0.05).
In addition to examining neuronal cells, we also exam-
ined peripheral immune cells from the spleen. We examined
numbers of T cells and numbers of MHCII+ cells (which includes
macrophages and B cells), as well as CD95 expression on these
cells. The results showed that levetiracetam treatment resulted in
no significant effect on the number of CD3+ T cells (Figure 3A),
MHCII+ (Figure 3B) cells, nor on the levels of CD95 expression
by T cells (Figure 3C), and non-T cells (Figure 3D). In addition,
we examined overall levels of MHCII and CLIP on non-T cells
(Figures 4A,B) to address the possibility that levetiracetam alters
immunogenicity of peripheral immune cells. No changes were
observed for either of these variables (Figures 4A,B). To further
detect levetiracetam-induced changes in processing or presenta-
tion by immune cells, we assessed lysosomal acidity and found no
significant changes (Figure 4C).
DISCUSSION
Levetiracetam is well established as a beneficial anti-seizure med-
ication and as an adjunct to other anti-seizure medications. The
molecular mechanisms accounting for the efficacy of levetirac-
etam for seizure activity are largely unknown. The results from
the present study suggest that levetiracetam induces expression
of CD95 and CD178 on NGF-treated C17.2 neuronal cells. The
results also demonstrate that the increased m∆Ψ in response to
levetiracetam on C17.2 neuronal stem cells requires the presence
of NGF. This is likely due to the differentiating effect of NGF
on neural stem cells. In contrast, the study shows that levetirac-
etam lowers the m∆Ψ of splenocytes and this effect is dependent
on intact invariant chain. These results suggest that both neuronal
and non-neuronal anti-epileptic activities of levetiracetam involve
control over energy metabolism, more specifically, m∆Ψ.
Epilepsy has traditionally been considered primarily a neuronal
disease. Growing evidence also implicates astrocytes, microglia,
peripheral leukocytes, and blood–brain barrier breakdown in the
pathogenesis of epilepsy. Here, we show two novel observations
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FIGURE 2 | Levetiracetam alters cell surface Fas expression on C17.2 cells. Mean flouresecence intensity (MFI) as measure of relative expression level of
(A) CD95, (B) CD178, (C) CD80, and (D) CD86 48 h after treatment with or without Lev. *Denotes a p-value<0.05.
that potentially link peripheral leukocytes to neurons. Our results
suggest that levetiracetam affects mitochondrial energy metabo-
lism as reflected by changes in m∆Ψ. Interestingly, these changes
are inversely related when comparing splenocytes to NGF-treated
neuronal stem cells. That is, levetiracetam causes a statistically sig-
nificant increase in the membrane potential of NGF-treated C17.2
cells and a significant decrease in m∆Ψ of levetiracetam-treated
spleen cells. It is pertinent to note that in mice deficient for CD74,
the levetiracetam-induced change to splenocyte m∆Ψ was ame-
liorated. Thus, it is possible that levetiracetam-induced changes in
mitochondrial activity result from cell–cell contact because CD74
can be expressed on the cell surface and mediate interactions with
other cells through its cognate ligand, CD44. Alternatively, the
requirement for CD74 to see the effects.
Previous studies have suggested that mitochondrial dysfunc-
tion contributes to the epileptic condition (23). The putative func-
tional significance of levetiracetam-induced alterations to m∆Ψ
in the epileptic brain is its known effects on proton transport.
Previous studies have demonstrated that alterations to the m∆Ψ in
neurons (24) and non-neuronal cells (25), directly influences ion
concentrations in the cytosol, thereby influencing plasma mem-
brane potential. Alterations to m∆Ψ have also been shown to
influence oxidative stress (26), which may be another anti-epileptic
mechanism. A third potential mechanism through which altered
m∆Ψ could influence seizures is by altering the cytosolic pH.
An acidification of cytosol as a result of protonation is known to
hyperpolarize the plasma membrane (27), which may raise the
seizure threshold. Support for this latter suggestion is observed in
epileptic hippocampal slices where the pattern of epileptic activity
corresponds to m∆Ψ and ion concentration (23).
Previous work from our lab demonstrated that Fas/FasL inter-
actions can facilitate neurite outgrowth subsequent to nerve
crush injury (28). CD95 and its ligand CD178, a member of
the NGF/NGF receptor superfamily of death-inducing receptor–
ligand pairs. Many members of this superfamily are involved in
cell fate decisions including cell death, cell proliferation, and dif-
ferentiation. We addressed the possibility that if levetiracetam
altered mitochondrial activity, it might also affect CD95 expres-
sion because elevated m∆Ψ can be associated with elevated CD95.
The results from the current study are consistent with this idea
because we found that in neuronal cells, in the presence of NGF and
>0.15 mM levetiracetam, m∆Ψ is increased as is Fas expression.
Therefore, levetiracetam may be involved in stabilizing m∆Ψ in
the presence of elevated levels of NGF.
Another potential effect of levetiracetam on leukocytes could be
related to some of the side-effects associated with levetiracetam. In
particular, an increased incidence of pharyngitis and rhinitis has
been observed in levetiracetam-treated patients (13–18). These
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FIGURE 3 | Levetiracetam does not Alter Immune Cells in vitro. The
percentage of (A)T cells and (B) MHCII+ cells in splenocytes 48 h after
treatment with or without 0.15 mM Lev. Mean fluorescence intensity (MFI) as
measure of relative expression level of CD95 on (C)T cells and (D) MHCII+
cells in splenocytes 48 h after treatment with or without 0.15 mM Lev.
*Denotes a p-value<0.05.
FIGURE 4 | Levetiracetam does not alter antigen processing and
presentation machinery in vitro. Mean fluorescence intensity (MFI) as
measure of relative expression level of (A) MHCII+ and (B) CLIP on
splenocytes 48 h after treatment with or without Lev. (C) MFI Lysosensor
Green as a relative measure of lysosomal acidity of splenocytes 48 h after
treatment with Lev. *Denotes a p-value<0.05.
findings are consistent with a role for alterations to an effective
immune response that may involve alterations in CD74 expres-
sion and function. A second possibility is related to the finding of
reduced m∆Ψ in splenocytes, which may reflect altered levels of
immune function, including increased inflammation accounting
for pharyngitis and rhinitis.
Overall, the data from the current study indicate that leve-
tiracetam differentially affects the m∆Ψ of neuronal C17.2 and
non-neuronal splenocytes. The results also show that in the pres-
ence of elevated NGF, neuronal C17.2 cells express CD95 and
CD178. The results from this study could help to explain some
of the mechanisms of action of levetiracetam, including some of
its side-effects. More studies are needed to better understand the
implications of these findings so that more efficacious treatments
with minimal side-effects can be developed.
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